The novel anti- cancer compounds KGP18 and KGP156 — the combined results of a collaboration between OXiGENE, Inc with Texas based researchers — has been issued Patent by US Patent and Trademark Office.
OXIGENE Inc. has been working with Kevin G. Pinney, Ph.D. and Mary Lynn Trawick, Ph.D.at Baylor University, Texas for the development of compounds that can block tubulin polymerization thereby acting as vascular targeting agents to block nutritional supply to cancer cells. The collaboration is working on developing products like benzosuberenes (a novel anti- proliferative agent) and cathepsin L inhibitors (anti-invasive molecules). The anti–proliferative properties of benzosuberenes is attributed to inhibition of tubulin polymerization at colchicine binding site.
So far, compounds like KGP18 and KGP156 have been developed that are comparatively small molecules that can effectively display depolymerizing anti- cancer activity in human tissues. Experimental studies on animal models like mice suggest that these compounds also exert their anti- tumor function by disrupting endothelial cell, capillary network leading to decreased blood supply to tumor cells.
The proposed mechanism of action and activity has been published in scientific journals on the developed compounds of benzosuberenes series. Details about the compounds is available at (bioorg. med. chem. 16:8161-8171 (2008); and Med. Chem. Commun. 3:720-24 (2012).
Dr. Pinney, Professor of Chemistry at Baylor University comments:
“This benzosuberene series of molecules are among the most potent antiproliferative agents identified to date in our laboratories, and we believe this exceptional potency coupled with their antivascular activity make these compounds potentially well-suited for selective delivery strategies, including their use as payloads for antibody-directed therapy,”
Patent number 8,397,859 is assigned to the OXiGENE, Inc, cover KGP18 and KGP156 and other benzosuberene compounds. Peter J. Langecker, M.D., Ph.D., OXiGENE’s Chief Executive Officer, commented that the issuance of this Patent has increased credibility and value to OXiGENE’s anti-cancer compounds. He is hopeful that further clinical development will open new treatment modalities for cancer treatment, and he is confident that the continuing contribution of researchers at Baylor University will add to the productivity of anti- proliferative regimen.